Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inverness’ even bigger bid for Biosite puts ball back in Beckman’s court

This article was originally published in The Gray Sheet

Executive Summary

Latest salvo in the bidding war for heart test maker Biosite comes from Inverness Medical Innovations, raising its offer to $92.50 per share. Biosite recently inked an amended deal with Beckman Coulter valued at $90 per share to match Inverness' prior unsolicited proposal. Biosite says it is weighing the latest Inverness offer (1"The Gray Sheet" May 7, 2007, In Brief)...

Related Content

Inverness and Biosite make it official
Beckman Coulter sweetens Biosite bid to $1.67 billion



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts